X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.467
-0.006 (-1.33%)
At close: Feb 21, 2025, 4:00 PM
0.470
+0.003 (0.62%)
After-hours: Feb 21, 2025, 6:03 PM EST
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $560.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $1.12M.
Revenue (ttm)
$1.12M
Revenue Growth
n/a
P/S Ratio
83.23
Revenue / Employee
$12,075
Employees
93
Market Cap
79.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
XFOR News
- 3 days ago - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - GlobeNewsWire
- 16 days ago - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - GlobeNewsWire
- 19 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire